Cardinal Health (CAH) shares fall after Q4 2025 revenue miss
Cardinal Health shares closed down 3.1% on Tuesday, settling at $204.63, after the healthcare distributor reported fourth-quarter fiscal 2025 revenue that missed analyst expectations. The decline followed Monday's close of $211.18, extending a recent downward trajectory for the stock.
The company announced fourth-quarter fiscal 2025 revenue of $60.2 billion, falling short of the $60.92 billion anticipated by analysts, despite achieving flat year-over-year growth. This revenue miss overshadowed several positive corporate developments, including raised fiscal 2026 earnings guidance and the acquisition of Solaris Health, a urology MSO with over 750 providers. Cardinal Health also reported adjusted free cash flow of $2.5 billion for fiscal 2025, projecting $2.75 billion to $3.25 billion for fiscal 2026.
The market's focus on the revenue shortfall suggests that the positive outlook and strategic acquisition were insufficient to offset immediate concerns regarding top-line performance. The stock's movement on 21 April 2026 marked a notable daily decline for the large healthcare services provider.
Why Cardinal Health's Revenue Miss Overshadowed Positive News
Cardinal Health operates as a vital intermediary in the healthcare supply chain, distributing pharmaceuticals, medical products, and laboratory items to hospitals, pharmacies, and other healthcare providers across the United States. Their business essentially ensures that critical supplies reach patients and practitioners efficiently, earning revenue through the volume and value of the products they move, alongside related services.
The primary factor behind Cardinal Health's share movement on 21 April 2026 was its fourth-quarter fiscal 2025 revenue falling short of analyst expectations. The company reported revenue of $60.2 billion, which was less than the $60.92 billion anticipated by analysts, despite achieving flat year-over-year growth. This revenue shortfall took precedence over other positive developments, such as raised fiscal 2026 earnings guidance and the strategic acquisition of Solaris Health, a urology MSO.
This focus on the top-line performance meant that Cardinal Health's shares closed down 3.1% on the day, ending the session at $204.63. The market reacted directly to the gap between what was delivered and what was expected.
Consider a chef who prepares an exquisite meal, featuring perfectly cooked dishes and innovative flavours, but accidentally serves slightly smaller portions than advertised on the menu. Despite the high quality of the food and the overall positive dining experience, customers might still feel a little let down by the portion size not meeting their initial expectation, impacting their overall perception of value.
Cardinal Health
Cardinal Health, Inc. (CAH) operates as an integrated healthcare services and products provider across the United States, Canada, Europe, and Asia. It delivers tailored solutions to a broad spectrum of healthcare entities, including hospitals, pharmacies, and ambulatory surgery centres. The company's operations are divided into two primary segments: Pharmaceutical and Medical. The Pharmaceutical segment focuses on distributing branded and generic pharmaceuticals, specialty products, and over-the-counter items, alongside offering services to manufacturers and providers, operating nuclear pharmacies, and managing medication therapy. The Medical segment manufactures, sources, and distributes a wide array of Cardinal Health branded medical, surgical, and laboratory products, encompassing gloves, needles, wound care, and surgical drapes, while also providing supply chain services. Incorporated in 1979, Cardinal Health is headquartered in Dublin, Ohio.